(Q37195587)

18 August 2017

CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality (English)

1 reference

18 August 2017

1 reference

3

N J Cox

1 reference

18 August 2017

1

M J Ratain

1 reference

18 August 2017

Y Nakamura

2

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 August 2013

1 reference

Clinical Pharmacology & Therapeutics

18 August 2017

1 reference

18 August 2017

94

1 reference

18 August 2017

2

1 reference

18 August 2017

185-187

1 reference

Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782290

Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782290

Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782290

Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782290

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782290

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782290

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782290

CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782290

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782290

Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3782290

3 September 2018

Identifiers

DOI

10.1038/CLPT.2013.66

1 reference

Dimensions Publication ID

18 August 2017

0 references

1 reference

18 August 2017

PubMed publication ID

23872831

1 reference